« Return to News | CROs/Service Providers

Theorem relocates headquarters to accommodate growth

Thursday, August 2, 2012 12:24 PM

Theorem Clinical Research, a midsize CRO that provides core clinical research and development services, has relocated its headquarters 1.5 miles from the original site in King of Prussia, Penn., where the company has been located for the past 10 years.

The new location was custom designed and will provide staff a spacious work environment and enhance the company’s flexibility and capabilities to provide clinical research and development services for its clients.

Theorem increased its new clientele during the past year, leading its executive administrators to decide to relocate to 1016 W. Ninth Ave.

According to Theorem’s CEO, John Potthoff, the move was needed to accommodate the company’s increasing number of employees. Potthoff predicts the new space will also enhance internal communication, generating better results for its clients.

“We have been anxiously waiting for this day,” Potthoff said. “It’s wonderful to be in our new office. As we grow, we continue to expand our capabilities to better serve our clients around the globe.” 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.